Back to top
more

Abbott Laboratories (ABT)

(Real Time Quote from BATS)

$111.09 USD

111.09
531,758

+0.15 (0.14%)

Updated Aug 16, 2024 10:16 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Sheraz Mian headshot

Top Stock Reports for JPMorgan Chase, Home Depot & Salesforce

Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), The Home Depot, Inc. (HD) and Salesforce, Inc. (CRM).

Avantor (AVTR) Q3 Earnings In-Line With Estimates, Revenues Top

Despite Avantor's (AVTR) continued stability in end markets, it reports an overall soft third-quarter performance.

Revvity (RVTY) Misses on Q3 Earnings, Lowers '23 EPS View

Revvity's (RVTY) third-quarter results reflect the impact of increased market uncertainty. The company's earnings and sales miss their respective estimates.

Integer Holdings (ITGR) Q3 Earnings Top Estimates, FY23 View Up

Integer Holdings' (ITGR) third-quarter results reflect robust Medical Sales, along with strength in the majority of the product lines.

Merit Medical (MMSI) Q3 Earnings Top Estimates, FY23 View Revised

Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the third quarter.

DexCom (DXCM) Beats on Q3 Earnings, Raises Sales Outlook

DexCom's (DXCM) third-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.

CONMED (CNMD) Beats on Q3 Earnings, Ups '23 EPS View

CONMED's (CNMD) adjusted third-quarter earnings and sales beat estimates on the back of strong growth in the U.S and international markets. Gross margin improves.

West Pharmaceutical (WST) Beats on Q3 Earnings, HVP Drives Sales

West Pharmaceutical's (WST) third-quarter results reflect a strong demand for non-COVID-19 demand, especially HVP devices.

Teladoc Health (TDOC) Q3 Loss Narrows on Integrated Care Strength

Teladoc Health's (TDOC) Q3 results were aided by membership growth in the Integrated Care unit as well as strong BetterHelp revenues. Management presently expects 2023 net loss per share to be within $1.50-$1.40.

ZBH or ABT: Which Is the Better Value Stock Right Now?

ZBH vs. ABT: Which Stock Is the Better Value Option?

Nalak Das headshot

5 Stocks to Watch on Solid Revenues in Last Reported Quarter

We have narrowed our search to five U.S. corporate behemoths. These are: JPM, UNH, PG, ABT, FCX.

HCA Healthcare's (HCA) Q3 Earnings Miss on High Expense Level

HCA Healthcare's (HCA) Q3 results were hurt by an increase in salaries and benefits expenses. Management presently estimates 2023 EPS to be within $17.80-$18.50, compared with the prior-view of $17.70-$18.90 per share.

Shockwave Medical (SWAV) Announces IVL Studies' Positive Results

Shockwave Medical's (SWAV) latest announcement of two new publications validates the utility of IVL in complex nodular and eccentric calcium.

Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

Company News for Oct 19, 2023

Companies In The News Are: PG, ABT, STT, USB.

Geopolitical Conflicts in Middle-East in Focus

Geopolitical Conflicts in Middle-East in Focus.

Abbott (ABT) Q3 Earnings and Revenues Surpass, Margins Dip

Abbott (ABT) reports solid underlying base business performance in the third quarter of 2023.

Pre-Markets in Red on Mid-East Concerns, Q3 Earnings in Focus

U.S. stock futures are trading lower as the geopolitical conflicts between Israel and Palestine-based terrorist group Hamas heightened.

Abbott (ABT) Reports Q3 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Abbott (ABT) Beats Q3 Earnings and Revenue Estimates

Abbott (ABT) delivered earnings and revenue surprises of 3.64% and 3.60%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Intuitive Surgical (ISRG) to Post Q3 Earnings: What's in Store?

Intuitive Surgical's (ISRG) third-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs might have hurt margins.

Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?

Smart Beta ETF report for NOBL

Should You Buy Abbott (ABT) Ahead of Earnings?

Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

(ABT) Gains As Market Dips: What You Should Know

Abbott (ABT) closed at $90.87 in the latest trading session, marking a +0.75% move from the prior day.

Will Abbott (ABT) Beat Estimates Again in Its Next Earnings Report?

Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.